Want to see ACIU full AI Analyst Report?

AC Immune SA (ACIU) Drug Pipeline

560 Followers

Aci-19764 At Dose A1, Aci-19764 At Dose A2, Aci-19764 At Dose A3, Aci-19764 At Dose A4, Aci-19764 At Dose A5, Aci-19764 At Dose A6, Aci-19764 At Dose B1, Aci-19764 At Dose B2, Aci-19764 At Dose B3, Aci-19764 At Dose C1

Healthy Participants, Obesity, Type 2 Diabetes Mellitus (T2dm)

Phase I

Recruiting

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors

Feb 18, 2026

[18F]Aci-19626

Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease (Ad), Frontotemporal Dementia (Ftd), Tdp-43 Proteinopathies, Suspected Limbic Predominant Age-Related Tdp-43 Encephalopathy (Late)

Early Phase I

Recruiting

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Mar 18, 2025

[18F]Aci-15916

Parkinson's Disease (Pd), Multiple System Atrophy (Msa), Dementia With Lewy Bodies (Dlb)

Early Phase I

Recruiting

[18F]ACI-15916 PET in α-synucleinopathies

Mar 18, 2025

Aci-7104.056 At Dose A, Aci-7104.056 At Dose B, Aci-7104.056 At Dose C

Parkinson Disease, Parkinson Disease 6, Early-Onset

Phase II

Active Not Recruiting

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Aug 04, 2023

―

Aci-24.060 At Dose A, Aci-24.060 At Dose B, Aci-24.060 At Dose C, Aci-24.060 At Dose D, Aci-24.060 At Dose X, Aci-24.060 At Dose Y

Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease In Down Syndrome

Phase I/II

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Jul 12, 2022

Aci-35.030, Jaci-35.054

Alzheimer's Disease, Dementia, Mild Cognitive Impairment, Cognitive Impairment, Brain Diseases, Central Nervous System Diseases, Tauopathies

Phase I/II

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Jun 22, 2020

―

FAQ

What are the FDA phases for drug approval?

The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

What is a clinical trial?

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

What drugs does AC Immune SA (ACIU) have in its pipeline

ACIU is currently developing the following drugs: Aci-19764 At Dose A1, Aci-19764 At Dose A2, Aci-19764 At Dose A3, Aci-19764 At Dose A4, Aci-19764 At Dose A5, Aci-19764 At Dose A6, Aci-19764 At Dose B1, Aci-19764 At Dose B2, Aci-19764 At Dose B3, Aci-19764 At Dose C1, [18F]Aci-19626, [18F]Aci-15916. These drug candidates are in various stages of clinical development as the company works toward FDA approval.